IP Library Granted Patent US 8,657,952
Granted Patent B2
US 8,657,952 · App. 11/739,416 · Granted Feb 25, 2014

Bone graft substitute composition

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,657,952
App. No.
11/739,416
Granted
Feb 25, 2014
Kind
B2
Abstract

A composition includes calcium sulfate hemihydrate, stearic acid, an accelerant, and a mixing solution. The composition can be injected, e.g., through a needle, and is capable of setting, e.g., in vivo, in a relatively short period of time to a relatively high hardness.

Claims (19)

1. A bone graft substitute composition kit, comprising: a powder mixture comprising greater than about 90 weight percent calcium sulfate hemihydrate, an accelerant for accelerating conversion of calcium sulfate hemihydrate to calcium sulfate dihydrate, the accelerant being selected from calcium sulfate dihydrate and calcium sulfate dihydrate coated with sucrose and present in an amount of less than about 0.5 percent by weight of the powder mixture, and stearic acid in an amount of at least about 1.0 percent by weight of the powder mixture; and an aqueous mixing solution.

2. The bone graft substitute composition kit of claim 1 , wherein the powder mixture comprises greater than about 95 weight percent calcium sulfate hemihydrate.

3. The bone graft substitute composition kit of claim 1 , wherein the accelerant comprises calcium sulfate dihydrate coated with sucrose.

4. The bone graft substitute composition kit of claim 1 , wherein the aqueous mixing solution is a saline solution.

5. The bone graft substitute composition kit of claim 1 , wherein the aqueous mixing solution comprises at least one inorganic salt or at least one cationic surface-active agent.

6. The bone graft substitute composition kit of claim 1 , wherein the powder mixture comprises about 0.1 to about 0.5 weight percent of said accelerant.

7. The bone graft substitute composition kit of claim 1 , wherein the powder mixture comprises about 1.0 to about 2.0 weight percent of stearic acid.

8. The bone graft substitute composition kit of claim 1 , wherein the kit further comprises an additive selected from the group consisting of an antiviral agent, an antimicrobial agent, an antibiotic agent, an amino acid, a peptide, a vitamin, an inorganic element, a protein synthesis co-factor, a hormone, an endocrine tissue, an enzyme, a polymer cell scaffolding agent with parenchymal cells, an angiogenic drug, demineralized bone powder, a collagen lattice, an antigenic agent, a cytoskeletal agent, mesenchymal stem cells, an antitumor agent, bone marrow, fibronectin, a growth hormone, an immunosuppressant, a nucleic acid, a growth factor, a surface active agent, a calcium phosphate material, a calcium carbonate material, a penetration enhancer, sodium bicarbonate, a bone allograft, and cancellous bone chips.

9. The bone graft substitute composition kit of claim 1 , wherein the kit further comprises an additive selected from the group consisting of antibiotics, chemotherapeutic agents, growth factors, analgesics, and demineralized bone matrix.

10. The bone graft substitute composition of claim 1 , wherein the bone graft substitute composition produced by mixing said powder mixture and said aqueous mixing solution has a Vicat set time of about 5 to about 10 minutes.

11. The bone graft substitute composition of claim 1 , wherein the accelerant is present in an amount of about 0.1 to about 0.5 weight percent, and the stearic acid is present in an amount of about 1.0 to about 2.0 weight percent.

12. The bone graft substitute composition kit of claim 11 , wherein the powder mixture comprises greater than about 95 weight percent calcium sulfate hemihydrate.

13. The bone graft substitute composition kit of claim 11 , wherein the accelerant comprises calcium sulfate dihydrate coated with sucrose.

14. The bone graft substitute composition kit of claim 11 , wherein the aqueous mixing solution is a saline solution.

15. A method of preparing a bone graft substitute composition, comprising: providing a powder mixture comprising greater than about 90 weight percent calcium sulfate hemihydrate, an accelerant for accelerating conversion of calcium sulfate hemihydrate to calcium sulfate dihydrate, the accelerant being selected from calcium sulfate dihydrate and calcium sulfate dihydrate coated with sucrose and present in an amount of less than about 0.5 percent by weight of the powder mixture, and stearic acid in an amount of at least about 1.0 percent by weight of the powder mixture; and mixing the powder mixture with an aqueous mixing solution to form a bone graft substitute composition that has a Vicat set time of about 5 to about 10 minutes.

16. A method of delivering a bone graft substitute composition, comprising: providing a powder mixture comprising greater than about 90 weight percent calcium sulfate hemihydrate, an accelerant for accelerating conversion of calcium sulfate hemihydrate to calcium sulfate dihydrate, the accelerant being selected from calcium sulfate dihydrate and calcium sulfate dihydrate coated with sucrose and present in an amount of less than about 0.5 percent by weight of the powder mixture, and stearic acid in an amount of at least about 1.0 percent by weight of the powder mixture; mixing the powder mixture with an aqueous mixing solution to form a bone graft substitute composition that has a Vicat set time of about 5 to about 10 minutes; and delivering the bone graft substitute composition to the site of a bone defect.

17. The method of claim 16 , wherein said delivering step comprises injecting the bone graft substitute composition through a needle prior to setting of the composition, such that the composition sets in vivo.

18. The bone graft substitute composition of claim 1 , wherein the bone graft substitute composition produced by mixing said powder mixture and said aqueous mixing solution is injectable through a needle.

19. The bone graft substitute composition of claim 1 , wherein the accelerant is present in an amount of less than about 0.3 percent by weight of the powder mixture, and stearic acid in an amount of at least about 1.5 percent by weight of the powder mixture.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Nov 19, 2020
From: MIDCAP FUNDING IV TRUST
To: SOLANA SURGICAL, LLC; ORTHOPRO, L.L.C.; WRIGHT MEDICAL GROUP N.V.; WRIGHT MEDICAL GROUP, INC.; BIOMIMETIC THERAPEUTICS CANADA, INC.; BIOMIMETIC THERAPEUTICS, LLC; BIOMIMETIC THERAPEUTICS USA, INC.; INBONE TECHNOLOGIES, INC.; ORTHOHELIX SURGICAL DESIGNS, INC.; TORNIER US HOLDINGS, INC.; TORNIER, INC.; TROOPER HOLDINGS INC.; WHITE BOX ORTHOPEDICS, LLC; WRIGHT MEDICAL CAPITAL, INC.; WRIGHT MEDICAL TECHNOLOGY, INC.; WRIGHT MEDICAL GROUP INTELLECTUAL PROPERTY, INC.
Reel/Frame 054480/0001 →
SECURITY INTEREST Recorded Jan 5, 2017
From: WRIGHT MEDICAL TECHNOLOGY, INC.
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 041257/0126 →